Compare Ascendis Pharma A/S (ASND) vs Valero Energy Corporation (VLO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Valero Energy Corporation — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Valero Energy Corporation trades at $285.35 (market cap $83.35B). The key difference: Valero Energy Corporation is far larger — about 4.7× Ascendis Pharma A/S's market cap, and Valero Energy Corporation pays a 1.71% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | VLO | |
|---|---|---|
Market Cap | $17.74B | $83.35B |
Sector | Health | Energy |
52-Week High | $277.18 | $282.88 |
52-Week Low | $163.32 | $131.77 |
Enterprise Value | $18.11B | $89.10B |
Dividend Yield | — | 1.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Valero Energy (VLO) trades at $280.69, down 0.2% on the day, with strong technical momentum as the stock approaches resistance near $285. The company has consistently beaten earnings estimates for three consecutive quarters, with Q2 2026 expected at $10.03 EPS. Fundamentals show solid profitability with 17.72% ROE and improving cash flow projections for 2026. Recent news highlights strong refining margins and Gulf Coast operational advantages supporting the bullish outlook.
VLO presents a compelling investment case with strong earnings momentum and favorable industry dynamics, though investors face risks from energy market volatility and declining revenue trends. The stock trades above the consensus price target of $257.57, suggesting limited near-term upside despite 58% analyst buy ratings. The upcoming dividend payment of $1.20 provides additional shareholder return potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Valero Energy Corporation
Valero Energy is one of the largest independent refiners in the United States. It operates 14 refineries with a total throughput capacity of 3.2 million barrels a day in the United States, Canada, and the United Kingdom. Valero also owns 14 ethanol plants with capacity of 1.7 billion gallons of ethanol a year and holds a 50% stake in Diamond Green Diesel, which has capacity to produce 700 million gallons per year of renewable diesel.
Read more on VLO →
